Appleton Partners Incma Lowers stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Appleton Partners Incma reduced its stake in Merck & Co. by 0.03% during the most recent quarter end. The investment management company now holds a total of 31,644 shares of Merck & Co. which is valued at $1,795,481 after selling 10 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.Merck & Co. makes up approximately 0.35% of Appleton Partners Incma’s portfolio.

Merck & Co. opened for trading at $56.06 and hit $56.62 on the upside on Wednesday, eventually ending the session at $56.31, with a gain of 0.48% or 0.27 points. The heightened volatility saw the trading volume jump to 69,41,426 shares. Company has a market cap of $156,275 M.

Other Hedge Funds, Including , Empirical Financial Services sold out all of its stake in MRK during the most recent quarter. The investment firm sold 4,312 shares of MRK which is valued $244,663.Berkshire Asset Managementpa boosted its stake in MRK in the latest quarter, The investment management firm added 15,244 additional shares and now holds a total of 163,612 shares of Merck & Co. which is valued at $9,185,178. Merck & Co. makes up approx 1.41% of Berkshire Asset Managementpa’s portfolio.Trust Co reduced its stake in MRK by selling 150 shares or 2.84% in the most recent quarter. The Hedge Fund company now holds 5,138 shares of MRK which is valued at $282,847. Merck & Co. makes up approx 0.13% of Trust Co’s portfolio.Chicago Trust Co Na reduced its stake in MRK by selling 1,937 shares or 3.55% in the most recent quarter. The Hedge Fund company now holds 52,585 shares of MRK which is valued at $2,894,804. Merck & Co. makes up approx 1.25% of Chicago Trust Co Na’s portfolio.

On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 3, 2016. Analyst had a consensus of $0.91. The company had revenue of $10215.00 million for the quarter, compared to analysts expectations of $10355.20 million. The company’s revenue was down -2.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.87 EPS.

Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.Merck & Co. was Downgraded by BofA/Merrill to ” Neutral” on Jan 27, 2016.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.